Gennao Bio

United States · Founded 2020 · $55.0M raised

Employees
1–10
Founded
2020
Business Model
B2B
Total Funding
$55.0M
Last Round
$15.0M Venture RoundNov 2022
Rounds
2

About

Gennao Bio is a privately held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing a proprietary gene monoclonal antibody (GMAB) platform technology. GMAB is an adaptive technology that uses a novel, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. This non-viral delivery platform is differentiated from traditional gene delivery systems as it can deliver multiple types of nucleic acids, allows for repeat dosing and employs well-established manufacturing processes. Gennao Bio is developing this delivery system with an initial focus on addressing significant unmet needs in oncology and rare monogenic skeletal muscle diseases.

Summary

Gennao Bio is a Biotech company based in United States, founded in 2020. It has raised $55.0M in total across 2 rounds, most recently a $15.0M Venture Round in Nov 2022. Investors include Logos Capital, OrbiMed and Surveyor Capital.

Tech & App Stack

7 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Venture RoundVenture RoundNov 2022
$15.0M

Sign up to see all 2 events

Funding: Series A through Venture Round. Amounts, valuations, and investors where available.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Gennao Bio on Indexed.vc
<a href="https://indexed.vc/companies/gennao-bio"><img src="https://indexed.vc/api/badge/company/gennao-bio" alt="Gennao Bio on Indexed.vc" width="260" height="76" /></a>